Selenium Nanoparticles as Candidates for Antibacterial Substitutes and Supplements against Multidrug-Resistant Bacteria
Open Access
- 13 July 2021
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 11 (7), 1028
- https://doi.org/10.3390/biom11071028
Abstract
In recent years, multidrug-resistant (MDR) bacteria have increased rapidly, representing a major threat to human health. This problem has created an urgent need to identify alternatives for the treatment of MDR bacteria. The aim of this study was to identify the antibacterial activity of selenium nanoparticles (SeNPs) and selenium nanowires (SeNWs) against MDR bacteria and assess the potential synergistic effects when combined with a conventional antibiotic (linezolid). SeNPs and SeNWs were characterized by transmission electron microscopy (TEM), X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), zeta potential, and UV-visible analysis. The antibacterial effects of SeNPs and SeNWs were confirmed by the macro-dilution minimum inhibitory concentration (MIC) test. SeNPs showed MIC values against methicillin-sensitive S. aureus (MSSA), methicillin-resistant S. aureus (MRSA), vancomycin-resistant S. aureus (VRSA), and vancomycin-resistant enterococci (VRE) at concentrations of 20, 80, 320, and >320 μg/mL, respectively. On the other hand, SeNWs showed a MIC value of >320 μg/mL against all tested bacteria. Therefore, MSSA, MRSA, and VRSA were selected for the bacteria to be tested, and SeNPs were selected as the antimicrobial agent for the following experiments. In the time-kill assay, SeNPs at a concentration of 4X MIC (80 and 320 μg/mL) showed bactericidal effects against MSSA and MRSA, respectively. At a concentration of 2X MIC (40 and 160 μg/mL), SeNPs showed bacteriostatic effects against MSSA and bactericidal effects against MRSA, respectively. In the synergy test, SeNPs showed a synergistic effect with linezolid (LZD) through protein degradation against MSSA and MRSA. In conclusion, these results suggest that SeNPs can be candidates for antibacterial substitutes and supplements against MDR bacteria for topical use, such as dressings. However, for use in clinical situations, additional experiments such as toxicity and synergistic mechanism tests of SeNPs are needed.Funding Information
- National Research Foundation of Korea (2019R1C1C1002490)
- Global Research Development Center (2018K1A4A3A01064257, 2019R1A6A1A11034536)
This publication has 72 references indexed in Scilit:
- Biosynthesis and structural characterization of selenium nanoparticles mediated by Zooglea ramigeraPowder Technology, 2013
- Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: The study, the patient, the bug or the drug?Journal of Infection, 2013
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistanceClinical Microbiology & Infection, 2012
- Surface decoration of selenium nanoparticles by mushroom polysaccharides–protein complexes to achieve enhanced cellular uptake and antiproliferative activityJournal of Materials Chemistry, 2012
- Nanoparticles of Selenium as Species with Stronger Physiological Effects in Sheep in Comparison with Sodium SeleniteBiological Trace Element Research, 2011
- Methicillin and vancomycin resistant S. aureus in hospitalized patientsJournal of Global Infectious Diseases, 2010
- Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other CancersJAMA, 2009
- Effect of Antibiotics on Staphylococcus aureus Producing Panton-Valentine LeukocidinAntimicrobial Agents and Chemotherapy, 2007
- Synergic in-vitro activity of imipenem and sulbactam against Acinetobacter baumanniiClinical Microbiology & Infection, 2004
- LinezolidDrugs, 2001